Derma Sciences scores $4.5 million BARDA contract
This article was originally published in Scrip
Executive Summary
Derma Sciences was awarded a $4.5 million 16-month grant from the US Biomedical Advanced Research and Development Authority (BARDA) to investigate the use of DSC127, an angiotensin analogue, in treating skin injuries associated with acute radiation exposure.